Ischemic Stroke, Acute
Conditions
Keywords
Ischemic Stroke, Antiplatelet Therapy, Intravenous Thrombolysis, Randomized Controlled Trial, Double Blind Study, Multicenter Study, Clinical Trial
Brief summary
Early antiplatelet therapy is promising for further improvement of functional prognosis on the basis of intravenous thrombolytic therapy. The primary purpose of this multicenter, randomized, double-blind, placebo-parallel controlled trial is to evaluate the efficacy and safety of the early dual antiplatelet therapy (within 6 hours of onset ) of ticagrelor with aspirin combined with intravenous thrombolysis in improving good functional outcome (mRS score 0-1) at 90 days inpatients with ischemic stroke.
Detailed description
Theoretically, early administration of antiplatelet therapy is expected to counteract platelet aggregation during intravenous thrombolysis, improving the efficacy of intravenous thrombolysis as well as the functional prognosis. According to current evidence, mainstream guidelines clearly state that the administration of intravenous aspirin (or other antiplatelet agents) within 24 hours of Recombinant tissue plasminogen activator (rt-PA) thrombolytic therapy is not recommended as an adjunctive treatment of intravenous thrombolysis therapy, despite the fact that rt-PA thrombolytic therapy is still acceptable for patients who have received antiplatelet therapy before the onset of stroke. Evidence from high-quality clinical trials for the routine use of oral antiplatelet drugs before and within 24 hours of intravenous thrombolysis in acute ischemic stroke (AIS) patients is quite limited. Meanwhile, trials including INSPIRES and CHANCE 2 have demonstrated that early initiation of dual antiplatelet therapy could significantly reduce the risk of recurrence and thus improve the functional prognosis without significantly increasing the risk of bleeding, providing a promising treatment for early oral antiplatelet therapy in patients undergoing intravenous thrombolysis. This trial is a multicenter, randomized, double-blind, placebo-parallel controlled designed clinical trial. A total of 1380 patients (aged 18-80 years) who have a new diagnosed ischemic stroke (within 6 hours of onset), a NIHSS score of 4-10 points, and have received/are planned to receive intravenous thrombolysis therapy with will be enrolled from 50 centers in China. Patients will be randomly assigned into intervention (dual antiplatelet therapy of Ticagrelor and Aspirin) and control group (placebo) by the ratio of 1:1. Face to face or distance (via video or telephone) interviews will be made at baseline, 7 ± 1 days, 30 ± 3 days, 60 ± 5 days and 90 ± 7 days after randomization. Primary outcome is defined as good functional outcomes (mRS score of 0-1 points) at 90 days. Secondary outcomes include neurologic improvement，quality of life ( quality-of-life EuroQol-5 Dimensions scale)，activity of daily living (Barthel index)，recurrent ischemic stroke. Safety outcomes, relating to antiplatelet and intravenous thrombolysis therapy (i.e., symptomatic intracranial hemorrhage, parenchymal hematoma type 2, bleeding events) will also be investigated. The Chi-square test was used to compare the proportion difference of good functional outcomes between two groups after 90 days of treatment, and the 95% confidence interval (CI) was calculated by using the Newcombe method. The generalized linear regression model was used to calculate the relative risk (RR) and its 95%CI. For survival outcomes, hazard ratio (HR) and 95% CI were calculated using the Cox proportional risk model.
Interventions
DRUGEarly Dual Antiplatelet Therapy
Day 1(within 6.0 hours of onset, before or after intravenous thrombolysis) : Ticagrelor (180mg) + Aspirin (100mg), one dose; Days 2-7: Ticagrelor (90mg/time, twice/day) + open-label Aspirin (100mg/time, once/day) ; Days 8-90: open-label Aspirin (100mg/time, once/day).
DRUGPlacebo
Day 1(within 6.0 hours of onset, before or after intravenous thrombolysis) : Placebo of Ticagrelor (180mg) + Placebo of Aspirin (100mg), one dose; Days 2-7: Placebo of Ticagrelor (90mg/time, twice/day) + open-label Aspirin (100mg/time, once/day) ; Days 8-90: open-label Aspirin (100mg/time, once/day).
Sponsors
Beijing Tiantan Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* 1\. 18-80 years old; 2\. Clinical diagnosis of acute ischemic stroke; 3\. Time from onset to treatment ≤6.0 hours; 4\. Having received or planning to receive intravenous thrombolytic therapy; 5\. NIHSS score of 4-10 points, and at least one of the 5th (upper limb exercise) or 6 th (lower limb exercise) scale is ≥1 point; 6\. Signed informed consent.
Exclusion criteria
* 1\. Planning to receive endovascular therapy; 2\. mRS scores ≥2 points before the onset; 3\. Receiving any antiplatelet therapy after the onset; 4\. Bleeding or other pathological brain disorders, such as vascular malformations, tumors, abscesses, or other common non-ischemic brain diseases (such as multiple sclerosis), identified by CT/MRI; 5\. Pre-existing clotting disorders, systemic bleeding, thrombocytopenia, or neutropenia; 6\. Pre-existing atrial fibrillation or anticoagulant therapy (warfarin, heparin, thrombin inhibitors or factor Xa inhibitors); 7\. Hepatic or renal insufficiency (hepatic insufficiency refers to the alanine transaminase (ALT) value \> 2 times the upper limit of normal value or aspartate aminotransferase (AST) times \> 2 times the upper limit of normal value; renal insufficiency refers to creatinine values \> 2 times the upper limit of normal value); 8\. Allergic to Ticagrelor or Aspirin or thier components and excipients; 9\. Women who are pregnant or breastfeeding, or those with negative pregnancy test records while refusing to use effective contraceptives; 10\. Having participated investigational drugs or device tests within 30 days; 11\. Being considered inappropriate to participate by researchers.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Excellent functional outcome | 90 days | Modified Rankin Scale (mRS) score of 0-1 points; The mRS score ranges from 0 to 6, with higher scores indicating worse functional outcome. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| mRS score of 0-2 points | 90 days | The mRS score ranges from 0 to 6, with higher scores indicating worse functional outcome. |
| Distribution of mRS score | 90 days | The distribution of mRS score of 0 to 6 points; The mRS score ranges from 0 to 6, with higher scores indicating worse functional outcome. |
| Neurologic improvement | 7 days | NIHSS score decreasing by 4 points or more than the value at baseline; The National Institutes of Health Stroke Scale (NIHSS) score ranges from 0 to 42, with higher scores indicating more severe neurological deficit. |
| Quality of life (EQ-5D scale) | 90 days | The European Quality of Life 5-Dimension（EQ-5D）questionnaire for measuring generic health status. The 5-level EQ-5D version (EQ-5D-5L) comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. The sum score on each of the five dimensions ranges from 5 (all domains have level 1) to 25 (all domains have level 5), with higher scores indicating worse health-related quality of life. |
| Activity of daily living (Barthel index ≥95 points) | 90 days | The Barthel index score ranges from 0 to 100, with higher scores indicating greater independence. |
| Recurrent ischemic stroke | 90 days | — |
| Symptomatic intracranial hemorrhage (ECASS-III) | 36 hours | — |
| Parenchymal hematoma type 2 (SIST-MOST) | 36 hours | — |
| Bleeding events (GUSTO) | 90 days | — |
| Adverse events | 90 days | — |
| Severe adverse events | 90 days | — |
Countries
China
Contacts
PRINCIPAL_INVESTIGATORYilong Wang, MD, PhD
Beijing Tiantan Hospital
Outcome results
None listed